Jun 20,2016

Netmedi starts cooperation with the German HELIOS Clinics

Netmedi has started a cooperation with the helios.hub in Berlin as a first step to apply Kaiku Health platform for the digital follow-up of cancer patients during their therapy and recovery at the cancer clinics of the HELIOS Kliniken in Germany. helios.hub is the eHealth accelerator of the HELIOS Kliniken, the largest privately owned clinic chain in Germany. helios.hub supports start-ups to develop, test and bring digital applications into the clinical practice.

COLLABORATION PARTNERSHIP

#r&d

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 19,2014

New Propeller Provider Dashboard Saves Time and Clicks

Propeller Health is excited to announce a new dashboard for health care providers is now live! The changes are direct result of the providers' feedback.

PRODUCT

#software

#rpm

View Analyst & Ambassador Comments
Go to original news
Dec 14,2022

Electronic Skin Patches Sales to Reach USD 29 Billion by 2027, Next-Gen Electronic Skin Patches to Witness Tremendous Demand. Abbott, Dexcom, GE, and Philips Set to Capatilize the Opportunity - Arizton

According to latest research report, the electronic skin patches market will grow at a CAGR of 20.17% during 2021-2027. A few exciting start-ups and universities are working to bring advanced electronic skin sensor patches into the market. For instance, XSENSIO SA has developed next-generation wearable devices to track biochemical information on the wearer's skin surface. Application areas of this technology includes diabetes management, remote patient monitoring, cardiovascular monitoring and others.

#rpm

View Analyst & Ambassador Comments
Go to original news
Nov 04,2022

Ascensia Launches Diabetes Management and Analytics Platform in the U.S

Ascensia Diabetes Care has launched its online diabetes management and analytics platform GlucoContro.online in the United States. Now available in more than 15 countries globally and in the process of further expansion, GlucoContro.online support diabetes management by enabling data-driven care for people using the CONTOUR® BGM portfolio. GlucoContro.online will be launched alongside CONTOUR®NEXT Concierge, Ascensia’s HCP-focused online platform for ordering CONTOUR meters and strips. With one login and within one uninterrupted system, HCPs will be able to rapidly access patient data as well as order essential supplies and samples from the CONTOUR® portfolio.

PRODUCT

#bgm

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 09,2022

IDTechEx Examines the Medical Devices for Remote Patient Monitoring of Chronic Conditions

Diabetes is one of the health conditions most commonly covered by RPM programs worldwide, and with good reason. Today, RPM programs by leading players such as Onduo, Omada and Livongo (Teladoc) provide connected glucometers, unlimited supplies of glucose test strips, and through digital health, personalized insights and expert coaching.

#rpm

#coaching

#bgm

View Analyst & Ambassador Comments
Go to original news
Nov 11,2022

Announcing Tidepool+, the next evolution of the Tidepool Data Platform

Tidepool’s Population Health Dashboard is the centerpiece to an evolution of the Tidepool Data Platform, called Tidepool+. With Tidepool+, Tidepool is introducing a premium offering that includes enhanced security controls like Single Sign-On, tools for direct patient engagement, and our Population Health Dashboard to empower Clinicians to sort, filter, and segment their patient lists based on a number of key factors.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 12,2022

How interoperability, increased reimbursement options will drive digital health in 2022

The digital health industry experienced a big growth year in 2021. According to Rock Health’s third quarter analysis of the space, funding had already reached $21.3 billion across 541 deals. The year surpassed 2020’s full-year funding total after the second quarter.

#rpm

#telehealth

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 02,2022

UCI Health Partners with Biofourmis for Hospital at Home and Post-Acute Remote Patient Monitoring

Biofourmis announced a multi-year agreement with UCI Health to support continuous artificial intelligence (AI)-powered remote monitoring of acute and post-acute care patients in their homes through Biofourmis tools. UCI Health comprises the clinical enterprise of the University of California, Irvine and is Orange County’s only academic health system. Biofourmis’ solutions will enable UCI Health to establish a virtual care platform for remote patient monitoring (RPM) and hospital-at-home initiatives.

COLLABORATION PARTNERSHIP

#institution

#rpm

#virtual care

View Analyst & Ambassador Comments
Go to original news
Feb 11,2022

Biofourmis Expands Into Virtual Specialty Care With The Launch Of Biofourmis Care

Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced the launch of Biofourmis Care, a first of its kind, technology-enabled care management service that delivers high-quality remote care for patients with chronic conditions. The service includes automated medication management to augment and assist care teams in remotely adjusting medications for optimal personalized therapy. Biofourmis Care currently includes five virtual care programs: heart failure, hypertension, diabetes, lipid management and atrial fibrillation.

PRODUCT

#rpm

#virtual care

View Analyst & Ambassador Comments
Go to original news
Feb 16,2022

Biofourmis Selected by Vanderbilt University Medical Center for CAR T-Cell Therapy Study Utilizing Tech-Enabled Remote Patient Monitoring

Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced today that Vanderbilt University Medical Center has selected Biofourmis to support a clinical study measuring the safety and efficacy of monitoring patients in a home-like outpatient setting after receiving a leading oncology drug. Patients with large B-cell lymphoma will receive the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (YESCARTA®) by Kite, a Gilead Company. In addition to periodic physical exams, several vital signs will be continuously monitored through Biofourmis’ analytics platform, which will assist the clinical team in detecting side effects of therapy to intervene as appropriate.

COLLABORATION PARTNERSHIP

#r&d

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to RPM